WO2005007832A3 - System for external control of oncolytic virus replication - Google Patents

System for external control of oncolytic virus replication Download PDF

Info

Publication number
WO2005007832A3
WO2005007832A3 PCT/US2004/005518 US2004005518W WO2005007832A3 WO 2005007832 A3 WO2005007832 A3 WO 2005007832A3 US 2004005518 W US2004005518 W US 2004005518W WO 2005007832 A3 WO2005007832 A3 WO 2005007832A3
Authority
WO
WIPO (PCT)
Prior art keywords
oncolytic virus
regulatory element
transcriptional regulatory
virus replication
external control
Prior art date
Application number
PCT/US2004/005518
Other languages
French (fr)
Other versions
WO2005007832A2 (en
Inventor
Thomas Harding
De Chao Yu
Original Assignee
Cell Genesys Inc
Thomas Harding
De Chao Yu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Genesys Inc, Thomas Harding, De Chao Yu filed Critical Cell Genesys Inc
Priority to CA002516652A priority Critical patent/CA2516652A1/en
Priority to EP04775799A priority patent/EP1597354A4/en
Priority to JP2006532296A priority patent/JP2007500012A/en
Publication of WO2005007832A2 publication Critical patent/WO2005007832A2/en
Publication of WO2005007832A3 publication Critical patent/WO2005007832A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compositions, methods and a system for external regulation of oncolytic virus replication are provided. The oncolytic virus contains a cell type-specific transcriptional regulatory element (CT-TRE) and an inducible transactivator regulated transcriptional regulatory element. The virus preferentially replicates in cells that allow a CT-TRE to function. In addition, the concentration of an inducing agent or condition is used to regulate a transactivator regulated transcriptional regulatory element, thereby providing at least two levels of control of oncolytic viral replication.
PCT/US2004/005518 2003-02-24 2004-02-24 System for external control of oncolytic virus replication WO2005007832A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002516652A CA2516652A1 (en) 2003-02-24 2004-02-24 System for external control of oncolytic virus replication
EP04775799A EP1597354A4 (en) 2003-02-24 2004-02-24 System for external control of oncolytic virus replication
JP2006532296A JP2007500012A (en) 2003-02-24 2004-02-24 System for external control of oncolytic virus replication

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45023203P 2003-02-24 2003-02-24
US60/450,232 2003-02-24

Publications (2)

Publication Number Publication Date
WO2005007832A2 WO2005007832A2 (en) 2005-01-27
WO2005007832A3 true WO2005007832A3 (en) 2005-12-15

Family

ID=34078982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/005518 WO2005007832A2 (en) 2003-02-24 2004-02-24 System for external control of oncolytic virus replication

Country Status (4)

Country Link
EP (1) EP1597354A4 (en)
JP (1) JP2007500012A (en)
CA (1) CA2516652A1 (en)
WO (1) WO2005007832A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1900749A1 (en) * 2006-09-12 2008-03-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nucleic acids for expressing a polynucleotide of interest in mammalian cancer cells
EE05711B1 (en) * 2009-10-07 2014-04-15 Tartu Ülikool Method and composition for the generation of conditionally lethal viral mutants and elimination of eukaryotic cell viability
CN101899420A (en) * 2010-01-16 2010-12-01 韩从辉 Method for preparing dual-regulated oncolytic adenovirus for expressed superantigen gene of targeted prostate tumor
CN114561430B (en) * 2022-03-25 2024-03-26 新乡医学院 expression vector for instantaneous expression of humanized cells, expression system, construction method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197293B1 (en) * 1997-03-03 2001-03-06 Calydon, Inc. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
US6692736B2 (en) * 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU744725B2 (en) * 1997-03-03 2002-02-28 Cold Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197293B1 (en) * 1997-03-03 2001-03-06 Calydon, Inc. Adenovirus vectors specific for cells expressing androgen receptor and methods of use thereof
US6692736B2 (en) * 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GU J. ET AL: "A novel single tetracycline-regulative adenoviral vector for tumor-specific Bax gene expression and cell killing in vitro and in vivo.", ONCOGEN., vol. 21, April 2002 (2002-04-01), pages 4757 - 4764, XP002979568 *
LI Y. ET AL: "Carconoembryonic antigen-producing cell-specific oncolytic adenovirus, OV798, for colorectal cancer therapy.", MOLECULAR CANCER THERAPY., vol. 2, September 2003 (2003-09-01), pages 1003 - 1009, XP008057987 *
See also references of EP1597354A4 *

Also Published As

Publication number Publication date
EP1597354A2 (en) 2005-11-23
EP1597354A4 (en) 2008-07-02
WO2005007832A2 (en) 2005-01-27
JP2007500012A (en) 2007-01-11
CA2516652A1 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
DK1228227T3 (en) Hankönssterile Brassica plants and methods for their preparation
DK0766330T3 (en) Ingredients for use in electrochemical cells and their use in oxygen separation
DK0770136T3 (en) Method of selecting high-expressing host cells
WO1999055627A8 (en) Stable oxidizing bromine formulations, methods of manufacture thereof and methods of use for microbiofouling control
BR0207733A (en) Process for regulating a thermodynamic process, especially a combustion process
DK1252323T3 (en) Virus strains for the oncolytic treatment of cancer
NO20052394L (en) Natural promoters for gene expression in CI metabolizing bacteria.
HK1080507B (en) Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
NO991742L (en) Lentiviral vectors
ATE430589T1 (en) WATER TREATMENT TO CONTROL BIOGROWTH USING STABILIZED BROMINE SOLUTIONS
WO2006038129A3 (en) Hepatitis c virus replication system
WO2004017450A3 (en) Device and method for humidifying a gas flow
WO2005007832A3 (en) System for external control of oncolytic virus replication
WO2006095242A3 (en) Fuel cell system
WO2003056912A3 (en) Inducible transposition in transgenic organism using transposon vector
Cheng et al. Advances on switched systems.
WO2004044182A3 (en) Highly permissive cell lines for hepatitis c virus replication
BR0113354A (en) Retroviral immunotherapy
DK1210446T3 (en) Modified ubiquitin regulatory system
BR0308736A (en) Cotton mouse virus lung cells
HUP9800113A2 (en) Transgenic virus
DE50304957D1 (en) RECOMBINANT VIRAL VECTORS FOR TETRACYCLINE REGULATORY GENE EXPRESSION
WO2004024867A3 (en) Vigilant vector system
WO2005056806A3 (en) Viral vectors controlled by a gene switch
Kim et al. Design Example of PCT Girder Bridge in the Curved Ramps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2516652

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004775799

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006532296

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004775799

Country of ref document: EP